RSLS
ReShape Lifesciences Inc.
-48.86%
$5.91 - $3.02
Feb 8th 2023 - Mar 22nd 2023
Feb, 16, 2023
$RSLS Nice consolidation phase before this one goes.
Feb, 8, 2023
$RSLS nice green boom boom after closed offering ... See more
TGTX
TG Therapeutics Inc
-19.05%
$18.43 - $14.92
Feb 7th 2023 - Mar 21st 2023
Mar, 13, 2023
The introduction of Briumvi reduces the infusion t... See more
Feb, 27, 2023
It bottomed in December at $0.55 and has since ris... See more
Feb, 16, 2023
$RSLS Nice consolidation phase before this one goes.
Feb, 8, 2023
$RSLS nice green boom boom after closed offering $FWBI new clinical study news $KPRX $CELZ $ICU
Jan, 3, 2023
$PBLA multiple phase 3 trail ..price 8 cents ..dirt cheap $KALA $RSLS $ATNF $PTPI
Jan, 31, 2023
$COSM 5.70 to 6.40 nice accumulation phase GL 6.22 test today.
Jan, 31, 2023
Study, PAYtience 📖💹💰
Jan, 20, 2023
$COSM Love these phases she goes through.
Jan, 18, 2023
Guys remember, they haven’t even dropped phase 2/3 clinic trial news yet 👀 $COMS Holding with absolutely no fear , definitely gonna leg up.
Jan, 9, 2023
$COSM gave this out to HKD and now I'm bullish on COSM let's see I like boring stocks or consolidation phases
Jan, 9, 2023
.pre split people=we are hardened Vets we have a 1000 yard stare nothing phases us.
Dec, 20, 2022
Study how that works and you will sleep well being a long tonight.
Dec, 17, 2022
This is a lower float than $COSM and there are potentially more positive catalysts ahead with their trials already meeting all endpoints.
Nov, 29, 2022
$COSM gastric bypass and bariatric surgery will have a new competitor in the Clinical Weight Loss realm, one that is much less risky, Cosmos Health new weight loss product will revolutionize weight loss as it is much less invasive.
Nov, 28, 2022
$COSM about to enter alpha Centauri phase 🪐
Mar, 13, 2023
The introduction of Briumvi reduces the infusion time to one hour, shortening the patients’ time spent in a clinical setting and allowing them to enhance their quality of life.”
Feb, 27, 2023
It bottomed in December at $0.55 and has since risen 300% on practically no news other than them having funding until 3Q23 and their primary pipeline item being an epilepsy drug currently in Phase 2.
Dec, 30, 2022
This is a very defined space and the physicians involved with the trials are well respected and known within the MS community cheers everyone
Dec, 20, 2022
up 290% After Positive Resmetirom Liver Treatment Phase3 Trial data.